IMV Marktkapitalisierung
Was ist das Marktkapitalisierung von IMV?
Marktkapitalisierung von IMV, Inc. ist $18.53M
Was ist die Definition von Marktkapitalisierung?
Die Marktkapitalisierung ist der Marktwert zu einem Zeitpunkt, zu dem die Aktien eines börsennotierten Unternehmens im Umlauf sind, und ist gleich dem Aktienkurs zu diesem Zeitpunkt multipliziert mit der Anzahl der im Umlauf befindlichen Aktien .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Marktkapitalisierung von Unternehmen in Health Care Sektor auf TSX im Vergleich zu IMV
Was macht IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Unternehmen mit marktkapitalisierung ähnlich IMV
- Pulse Oil hat Marktkapitalisierung von $18.50M
- Akme Star Housing Finance hat Marktkapitalisierung von $18.50M
- Namaste Technologies hat Marktkapitalisierung von $18.50M
- Ying Hai hat Marktkapitalisierung von $18.50M
- UrbanGold Minerals hat Marktkapitalisierung von $18.51M
- Subversive Capital Acquisition hat Marktkapitalisierung von $18.52M
- IMV hat Marktkapitalisierung von $18.53M
- Black Iron hat Marktkapitalisierung von $18.53M
- Clever Leaves hat Marktkapitalisierung von $18.54M
- Fe hat Marktkapitalisierung von $18.54M
- Optimumbank hat Marktkapitalisierung von $18.54M
- IL&FS Transportation Networks hat Marktkapitalisierung von $18.55M
- Shield Therapeutics Plc hat Marktkapitalisierung von $18.55M